STAT+: Orexin discoverers awarded prestigious Lasker award

STAT PlusNewsletterThe Readout Orexin discoverers awarded prestigious Lasker award A new FDA CBER head, AI company Schrodinger with a new startup, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Elaine Chen and Allison DeAngelisSept. 9, 2026 Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

You can reach Elaine on Signal at elaineywchen.70.Allison DeAngelis[email protected]Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. Want to stay on top of the science and politics driving biotech today?

Sign up to get our biotech newsletter in your inbox. First came the new teaser for Nathan Fielder’s documentary on Elizabeth Holmes. Now come the memes.

Bring it on.Advertisement FDA names permanent heads of drug and biologics centers For the past few months, key centers at the FDA have been led by acting officials. The agency said yesterday it will now make them permanent. Michael Davis will be director of the Center for Drug Evaluation and Research, and Karim Mikhail will be director of the Center for Biologics Evaluation and Research.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Allison DeAngelis Biotech Startups and Venture Capital Reporter Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech September 9, 2026 STAT Plus: Leukemia drug data suggested a different way to treat diabetes.

A new biotech will test that idea Biotech September 8, 2026 STAT Plus: FDA names acting heads of drug and vaccine centers to permanent roles Advertisement Health Tech Newsletter September 8, 2026 STAT Plus: Oura files to goes public, reported $1.2B in earnings The Readout September 8, 2026 STAT Plus: FDA approves AstraZeneca breast cancer drug Biotech September 8, 2026 STAT Plus: Inhibrx claims first win for long-sought immunotherapy target Subscriber Picks